ArQule to Report Fiscal 2013 Financial Results on March 5, 2014 Business Wire WOBURN, Mass. -- February 26, 2014 ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the fiscal 2013 year-end and fourth quarter on Wednesday, March 5, 2014 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. eastern time that day to discuss these results. Conference Call and Webcast Date: Wednesday, March 5, 2014 Time: 9:00 a.m., Eastern Time Conference Call Numbers Domestic (toll free): (877) 868-1831 International: (914) 495-8595 Webcast: www.arqule.com A replay of the conference call will be available beginning on March 5, 2014 two hours after the call’s completion for seven days and can be accessed by dialing toll-free (855) 859-2056 or (800) 585-8367 and outside the U.S. (404) 537-3406. The confirmation code for replayed calls is 31423627. About ArQule ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, and ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. Contact: ArQule, Inc. William B. Boni, 781-994-0300 VP, Investor Relations/ Corp. Communications www.ArQule.com
ArQule to Report Fiscal 2013 Financial Results on March 5, 2014
Press spacebar to pause and continue. Press esc to stop.